MAG: A Potential Drug Target for Myelin Sheath Maintenance (G4099)

Target Name: MAG

NCBI ID: G4099

Content of Review Report on MAG Target / Biomarker

MAG

MAG: A Potential Drug Target for Myelin Sheath Maintenance

MAG (Myelin Associated Glycoprotein) is a protein that is found in the central nervous system (CNS) and is known to be associated with the myelin sheath that surrounds nerve cells. It is a glycoprotein which means it consists of a protein and a carbohydrate. MAG is also known as protein C-type or P1G. MAG is a protein that is expressed in the CNS and is found in various tissues throughout the body. It is a scaffold protein which means it provides structural support to the myelin sheath. MAG is also known as a myelin-associated protein (MAP) and its function is to interact with the myelin sheath and help maintain the integrity of the myelin structure.

MAG is a transmembrane protein which means it spans the cell membrane and is associated with the intracellular signaling pathway. It is involved in many different signaling pathways in the CNS, including the regulation of pain, inflammation, and neurotransmitter release. MAG is also involved in the regulation of the growth and differentiation of nerve cells, as well as the regulation of the immune response.

MAG is a good candidate for a drug target because of its unique structure and its involvement in multiple signaling pathways. One of the main reasons why MAG is a good candidate for a drug target is its high level of expression in the CNS. MAG is expressed in higher amounts in the CNS than in other tissues, which means it is more sensitive to drug-mediated changes. Additionally, MAG is a good candidate for a drug target because of its role in multiple signaling pathways. It is involved in the regulation of pain, inflammation, and neurotransmitter release, which makes it a potential drug target for various neurological disorders.

Another reason why MAG is a good candidate for a drug target is its location in the CNS. MAG is mainly expressed in the diencephalon, which is the central part of the brain that contains the cerebral cortex, the basal ganglia, and other brain regions. This means that any drug that targets MAG in the CNS is likely to have a more targeted and effective effect on the disease.

MAG is also a good candidate for a drug target because of its structural features. MAG is a scaffold protein which means it provides structural support to the myelin sheath. It does this by interacting with the myelin associated protein (MAP) which is a protein that is also involved in the regulation of the myelin sheath. MAG and MAP work together to maintain the integrity of the myelin structure.

In addition, MAG is also a good candidate for a drug target because of its role in the regulation of pain. MAG is involved in the regulation of pain perception and release. It does this by interacting with the neurotransmitter GABA which is a chemical that inhibits pain. Additionally, MAG is also involved in the regulation of the neurotransmitter serotonin which is involved in regulation mood.

MAG is also a good candidate for a drug target because of its role in the regulation of inflammation. MAG is involved in the regulation of inflammation in the CNS. It does this by interacting with the immune cell PDGF which is a protein that is involved in the regulation of cell growth and differentiation. Additionally, MAG is also involved in the regulation of the immune response, which is important for the prevention of neurodegenerative diseases.

MAG is also a good candidate for a drug target because of its role in the regulation of neurotransmitter release. MAG is involved in the regulation of neurotransmitter release from the CNS. It does this by interacting with the neurotransmitter release protein (

Protein Name: Myelin Associated Glycoprotein

Functions: Adhesion molecule that mediates interactions between myelinating cells and neurons by binding to neuronal sialic acid-containing gangliosides and to the glycoproteins RTN4R and RTN4RL2 (By similarity). Not required for initial myelination, but seems to play a role in the maintenance of normal axon myelination. Protects motoneurons against apoptosis, also after injury; protection against apoptosis is probably mediated via interaction with neuronal RTN4R and RTN4RL2. Required to prevent degeneration of myelinated axons in adults; this probably depends on binding to gangliosides on the axon cell membrane (By similarity). Negative regulator of neurite outgrowth; in dorsal root ganglion neurons the inhibition is mediated primarily via binding to neuronal RTN4R or RTN4RL2 and to a lesser degree via binding to neuronal gangliosides. In cerebellar granule cells the inhibition is mediated primarily via binding to neuronal gangliosides. In sensory neurons, inhibition of neurite extension depends only partially on RTN4R, RTN4RL2 and gangliosides. Inhibits axon longitudinal growth (By similarity). Inhibits axon outgrowth by binding to RTN4R (By similarity). Preferentially binds to alpha-2,3-linked sialic acid. Binds ganglioside Gt1b (By similarity)

The "MAG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets